Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Summit Corporation PLC (SUMM)

  Print      Mail a friend

Wednesday 24 September, 2008

Summit Corporation PLC


Summit Corporation plc
("Summit plc" or "the Company")


Oxford, UK, 24 September 2008 - Summit Corporation plc (AIM: SUMM),
the leading UK biotechnology company, announces it has entered into a
co-development agreement for its clinical candidate SMT D001 with
Orient Pharma ("Orient"), the R&D and manufacturing subsidiary of
Taiwan-based Orient Europharma Co. Ltd.  SMT D001 is in a Phase II
clinical development programme as a treatment for sialorrhoea or
excessive drooling, a non-motor symptom of Parkinson's disease (PD)
and other neurological disorders.  A Phase I study indicated that SMT
D001 reduces saliva production by up to 40%.

Under the terms of the agreement, Orient will fund the development of
a novel buccal formulation of SMT D001 using its proprietary drug
delivery technology at a new FDA-approved manufacturing plant in

Summit retains exclusive development and commercialisation rights to
the new formulation of SMT D001 in North America, Europe and the rest
of the world, where it will continue seek partners to continue the
development and commercialisation of SMT D001. Orient gains exclusive
clinical development and commercialisation rights to the product in
Asia Pacific and Australasia with Summit having access to the
formulation and clinical trial data produced by Orient.  In addition,
Orient will only be responsible for the costs associated with the
development, manufacture and distribution of SMT D001 within its
respective territories.

Importantly, the buccal formulation will help deliver SMT D001
directly to the affected areas in patients with the aim of increasing
its efficacy in reducing excessive drooling and improving patient
compliance.  In addition, the development work will extend the
intellectual property protection around this programme to further
enhance its commercial value.  It is expected that the novel
formulation will be used in all future clinical trials which will
conform to FDA guidelines and as a result, Summit has suspended
recruitment in its on-going oral Phase II clinical trial.

Steven Lee, PhD, Chief Executive Officer of Summit said, "We are
pleased to be working with Orient in the development of SMT D001, a
company with a proven track record of developing approved drugs and
an expertise in the field of drug delivery technology and
formulation. This co-development deal with Orient enables us to
retain valuable commercial rights to this product for major world
territories, and to exploit the FDA-standard clinical results
generated by Orient in future licensing opportunities, ensuring no
future costs to Summit.

"For Summit, this agreement highlights the continued progress we are
making in fulfilling our strategy of signing early stage deals from
our pipeline of clinical and preclinical assets and I expect further
developments in the coming months."

                              - ENDS -

For more information, please contact:
Summit plc
Steven Lee, PhD, Chief Executive Officer
Richard Pye, PhD, Investor Relations
Tel: +44 (0)1235 443951; +44 (0)7825 313476
Citigate Dewe Rogerson
Mark Swallow, PhD / David Dible / Emma Palmer Foster
Tel: +44 (0)207 638 9571
Panmure Gordon
Andrew Burnett / Rakesh Sharma (Corporate Finance)
Ashton Clanfield (Corporate Broking)
Tel: +44 (0)207 459 3600

About Summit plc
Summit plc is a leading UK biotechnology company with a broad
preclinical and clinical pipeline, two world-leading technology
platforms and an innovative business model that is expected to
generate sustainable value for investors.
Summit is developing many drug programmes that target unmet medical
needs from which it intends to generate value by out-licensing
attractive late preclinical or early clinical stage programmes in
return for upfront, milestone and royalty payments. Summit uses its
scientific expertise to target orphan indications, neuro-disorders
and infectious diseases.
Summit's drug pipeline is supported by its world leadership in two
innovative technology platforms: carbohydrate chemistry and zebrafish
biology. These platforms support existing programmes and also will be
the source of future programmes to refuel Summit's drug pipeline.
These platform technologies also form the basis of the Company's
revenue generating service business.
The company listed on the alternative investment market (AIM) of the
London Stock Exchange in October 2004 - symbol: SUMM.  Further
information about the company is available at

About Orient Europharma

Founded in 1982, Orient Europharma (OEP) has five divisions: Pharma,
Nutricare, Dermo-Cosmetics, Oncology and Consumer Healthcare. The
company's leading products include hyaluronic acid injections and
Karihome Goat's Milk for infants and toddlers. Beginning in 1993, OEP
established subsidiaries in Hong Kong, Malaysia, Singapore and the
Philippines. It is now expanding into mainland China. In 2003, the
company listed on Taiwan's OTC market (stock code: 4120). For more
information, please visit
In 2007, OEP's net sales grew by 17.7 percent to NT$2.6 billion,
while after-tax net profits increased over 20 percent to NT$160
million with an EPS of NT$3.15. Total net sales reached NT$3.8
billion - an increase of 21.7 percent compared with NT$2.53 billion
in 2006. Total sales in the first quarter of 2008 rose to a new high
of NT$762 million -- a 19.4 percent year-on-year (YoY) over 2007. The
net sales in April amounted to NT$273 million. OEP was named an "A+
company"- the highest marks given by the Taiwan Stock Exchange's
Information Transparency and Disclosure Ranking in 2007.



a d v e r t i s e m e n t